|
|
|
Volumn 6, Issue 4, 2010, Pages 509-
|
|
Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DACLIZUMAB;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ADOLESCENT;
ADULT;
DOUBLE BLIND PROCEDURE;
HUMAN;
MIDDLE AGED;
MULTICENTER STUDY (TOPIC);
MULTIPLE SCLEROSIS;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ADOLESCENT;
ADULT;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE II AS TOPIC;
DOUBLE-BLIND METHOD;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
MIDDLE AGED;
MULTICENTER STUDIES AS TOPIC;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
YOUNG ADULT;
|
|
EID: 79958042652
PISSN: None
EISSN: 17448409
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|